HYBIO(SZ:300199)2022-12-06 08:26Group 1: Financial Performance - In the first three quarters of 2016, the raw material drug business achieved revenue of approximately 110 million CNY, with a year-on-year growth exceeding 500% [2] - The peptide business generated nearly 90 million CNY in revenue, reflecting a year-on-year increase of about 8% [2] - The market for carboprost, a synthetic long-acting oxytocin analog, is projected to reach 2 to 4 billion CNY due to an estimated annual increase of 2.5 million newborns following the full implementation of the two-child policy [4] Group 2: Market Expansion and Product Development - The company has established stable partnerships with several major pharmaceutical companies abroad, enhancing its competitiveness in the international raw material drug market [2] - The company has invested 10 years and 7 years in the R&D of the raw materials for liraglutide and glatiramer, respectively, leading to recognized production processes and competitive quality [2] - The non-invasive continuous blood glucose monitoring wristband project is actively progressing with clinical trials in Europe, aimed at improving the quality of life for diabetes patients [3] Group 3: Regulatory and Strategic Adjustments - The company terminated its third employee stock ownership plan due to significant changes in regulatory policies and market conditions, with plans to initiate a new stock ownership plan when conditions are favorable [5] - The company is actively researching national policies and market trends to adjust its marketing strategies and optimize product structure in response to domestic market challenges [4]